New Hampshire Patent of the Month – February 2025
Adimab has developed a groundbreaking antibody designed to combat respiratory syncytial virus (RSV) with unprecedented efficacy. RSV is a major cause of hospitalization in infants and severe respiratory illness in the elderly, yet treatment options remain limited. Existing antibodies like palivizumab offer only modest protection, highlighting the urgent need for more potent solutions.
Adimab’s novel antibody specifically targets the RSV fusion (F) protein in its prefusion state, the most vulnerable phase for neutralization. Unlike previous antibodies, this new candidate exhibits significantly enhanced binding affinity and neutralization potency against both RSV A and B subtypes. Laboratory tests demonstrate that it outperforms existing therapies by a factor of 5 to 100 in neutralization assays. This level of effectiveness means lower doses could achieve better protection, reducing the frequency of administration and the potential for side effects.
Beyond treatment, this antibody holds promise for RSV prevention. It could serve as a more accessible and effective prophylactic option for high-risk populations, including premature infants, immunocompromised patients, and elderly individuals with chronic lung or heart conditions. Additionally, its specificity for the prefusion F protein makes it a valuable candidate for vaccine development, potentially leading to long-term immunity against RSV.
With this innovation, Adimab sets a new benchmark in antibody engineering, leveraging advanced B-cell screening and protein optimization to deliver a transformative RSV therapy. By providing superior neutralization with lower dosages, this antibody represents a critical step forward in RSV treatment and prevention, offering hope for millions at risk of severe infection.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
